PNAS

How news producers can drive consumers toward misinformation - even when they want the truth

Retrieved on: 
Tuesday, March 5, 2024

Rand and his coauthors saw that this approach left out a fundamental piece of the equation — misinformation producers.

Key Points: 
  • Rand and his coauthors saw that this approach left out a fundamental piece of the equation — misinformation producers.
  • “Consumers don't just make unilateral choices about what they consume, but instead, their choices depend on the content that producers produce.
  • This is possible when two conditions are met: news producers can present different stories to different consumers using microtargeting and consumers are somewhat inattentive.
  • Right now, the deck may be stacked in misinformation producers’ favor — but as Rand and his team found, close attention puts consumers back in control.

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Tuesday, February 6, 2024

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Tuesday, February 6, 2024

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

Groundbreaking Study Demonstrates 20-Year Remission in Pemphigus Vulgaris Patients Using IVIg Therapy

Retrieved on: 
Wednesday, January 31, 2024

Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.

Key Points: 
  • Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.
  • Twenty-one patients with confirmed PV received IVIg therapy according to a specific protocol.
  • This long-term remission suggests that IVIg may help restore immune balance and tolerance in PV patients.
  • The pioneering research, offering sustained remission for pemphigus vulgaris patients, highlights the considerable potential of IVIg therapy.

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Retrieved on: 
Monday, January 8, 2024

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
  • “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
  • from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

Retrieved on: 
Thursday, December 21, 2023

BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

Key Points: 
  • The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM).
  • We believe DCVax-L can offer a much needed new treatment option for GBM patients, both alone and in combination with other treatment agents.
  • We look forward to bringing the treatment to as many patients as possible, including in community settings where most patients are treated."
  • The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors.

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

Retrieved on: 
Thursday, December 21, 2023

BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

Key Points: 
  • The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM).
  • We believe DCVax-L can offer a much needed new treatment option for GBM patients, both alone and in combination with other treatment agents.
  • We look forward to bringing the treatment to as many patients as possible, including in community settings where most patients are treated."
  • The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors.

CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors

Retrieved on: 
Wednesday, December 20, 2023

The successful completion of the first patient dosing of SY001  demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform.

Key Points: 
  • The successful completion of the first patient dosing of SY001  demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform.
  • Only 2 grade 3 adverse events occurred; Common grade 1 - 2 adverse events included fever, elevated C-reactive protein, etc.
  • Based on M-CAR, a functionally enhanced second generation CAR-iMAC has been developed to enhance the effectiveness of the therapy for solid tumors.
  • The mechanism of antigen-dependent activation and polarization of the second generation CAR-iMAC and the mechanisms of solid tumor cell killing were also revealed.

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Retrieved on: 
Thursday, November 9, 2023

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that it has selected a lead therapeutic candidate for its PAS-003 program, a proprietary humanized monoclonal antibody (mAb) that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis (ALS).

Key Points: 
  • Scientists at Pasithea have performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS.
  • This work included further validation of α5β1 integrin as a target in both familial (SOD1) and sporadic (TDP-43) ALS mouse models with reproducible improvements on behavior and survival.
  • Extensive mechanism of action studies link disease model efficacy to effects on the migration and adhesion of immune cells.
  • Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea commented, “We have chosen the most optimal anti-α5β1 humanized mAb for the treatment of both sporadic and familial ALS.

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof. Shun Lu to its Clinical Advisory Board

Retrieved on: 
Thursday, September 14, 2023

SAN DIEGO, Sept. 14, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company's Clinical Advisory Board (CAB).

Key Points: 
  • SAN DIEGO, Sept. 14, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company's Clinical Advisory Board (CAB).
  • "We are excited to have Professor Lu joining our Clinical Advisory Board," said Rita Laeufle, MD, PhD, Phanes' Chief Medical Officer. "
  • Professor Lu is a leading clinician-scientist in the field of lung cancer.
  • He also served on the International Affairs Committee (IAC) of American Clinical Oncology Society (2008-2011) and MCMC Working Group (2008-2016).